BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) went down by -0.06% from its latest closing price compared to the recent 1-year high of $18.48. The company’s stock price has collected 2.52% of gains in the last five trading sessions. Press Release reported on 09/09/21 that BioCryst Announces Approval of ORLADEYO(R) (berotralstat) in United Arab Emirates
Is It Worth Investing in BioCryst Pharmaceuticals Inc. (NASDAQ :BCRX) Right Now?
Plus, the 36-month beta value for BCRX is at 2.59. Opinions of the stock are interesting as 8 analysts out of 12 who provided ratings for BioCryst Pharmaceuticals Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $21.27, which is $5.79 above the current price. BCRX currently public float of 177.26M and currently shorts hold a 10.88% ratio of that float. Today, the average trading volume of BCRX was 2.93M shares.
BCRX’s Market Performance
BCRX stocks went up by 2.52% for the week, with a monthly drop of -4.15% and a quarterly performance of -0.83%, while its annual performance rate touched 284.12%. The volatility ratio for the week stands at 4.48% while the volatility levels for the past 30 days are set at 4.22% for BioCryst Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 1.49% for BCRX stocks with a simple moving average of 25.15% for the last 200 days.
Analysts’ Opinion of BCRX
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $21. The rating they have provided for BCRX stocks is “Overweight” according to the report published on August 03rd, 2021.
Cowen gave a rating of “Outperform” to BCRX, setting the target price at $16 in the report published on March 01st of the current year.
BCRX Trading at -2.85% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.23% of loss for the given period.
Volatility was left at 4.22%, however, over the last 30 days, the volatility rate increased by 4.48%, as shares surge +1.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.07% lower at present.
During the last 5 trading sessions, BCRX rose by +2.52%, which changed the moving average for the period of 200-days by +225.21% in comparison to the 20-day moving average, which settled at $15.26. In addition, BioCryst Pharmaceuticals Inc. saw 107.79% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BCRX starting from ABERCROMBIE GEORGE B, who sale 74,000 shares at the price of $15.09 back on Sep 10. After this action, ABERCROMBIE GEORGE B now owns 0 shares of BioCryst Pharmaceuticals Inc., valued at $1,116,660 using the latest closing price.
ABERCROMBIE GEORGE B, the Director of BioCryst Pharmaceuticals Inc., sale 5,000 shares at $15.69 during a trade that took place back on Jul 15, which means that ABERCROMBIE GEORGE B is holding 3,000 shares at $78,450 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -952.90 for the present operating margin
- +90.59 for the gross margin
The net margin for BioCryst Pharmaceuticals Inc. stands at -1026.35. The total capital return value is set at -131.36, while invested capital returns managed to touch -195.22. Equity return is now at value 513.80, with -79.80 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 61.66, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 1.16 and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.06.